Amgen
1Q Revenues: $7.4 billion (+22%)
1Q Loss: $113 million (earnings were $2.8 billion 1Q23)
Comments: Repatha (evolocumab) sales increased 33% to $517 million in the quarter, driven by 44% volume growth. TEZSPIRE (tezepelumab-ekko) generated $173 million of sales in the quarter, up 80%, primarily driven by volume growth. Otezla (apremilast) sales were $394 million, an increase of 1%.  Enbrel (etanercept) generated $567 million of sales, down 2%. AMJEVITA/AMGEVITA (adalimumab) generated $168 million of sales, up 2%. EVENITY (romosozumab-aqqg) sales increased 35% to $342 million, primarily driven by volume growth. BLINCYTO (blinatumomab) sales increased 26% to $244 million. TAVNEOS (avacopan) sales were $51 million, up 122% driven by volume growth. Prolia (denosumab) generated $999 million of sales, up 8% driven by volume growth Vectibix (panitumumab) sales were $247 million, up 6%. KYPROLIS (carfilzomib) sales increased 5% to $376 million. XGEVA (denosumab) sales increased 5% to $561 million. Nplate (romiplostim) generated $317 million of sales in the quarter, down 12%. MVASI (bevacizumab-awwb) sales were flat at $202 million.
 
Results include $914 million of sales from the Horizon Therapeutics acquisition, driven by TEPEZZA (teprotumumab-trbw), KRYSTEXXA (pegloticase) and UPLIZNA (inebilizumab-cdon). TEPEZZA (teprotumumab-trbw) generated $424 million of sales in the quarter. TEPEZZA is the first and only FDA-approved treatment for thyroid eye disease (TED). KRYSTEXXA (pegloticase) generated $235 million of sales. KRYSTEXXA is the first and only FDA-approved treatment for chronic refractory gout. UPLIZNA (inebilizumab-cdon) sales were $80 million in the quarter. UPLIZNA is used to treat adults with neuromyelitis optica spectrum disorders.